06.23.2026

Oculgen Announces First US Patient Enrolled in STAT Trial of OCUL101 for Wet AMD

Key Takeaways The first US participant has been enrolled in the phase 2/3 STAT trial evaluating OCUL101 for treatment-naïve wet AMD OCUL101 is a dual-target investigational biologic designed to bind both VEGF and complement C5, addressing angiogenic and inflammatory pathways implicated in AMD The global study plans to enroll approximately 255 participants across 70 sites in the United States and Europe Shenzhen Oculgen Biomedical Technology Co. (Oculgen) announced that the first US participant has been enrolled in the phase 2/3 STAT study (NCT07520318), which is evaluating the investigational agent OCUL101 in adults with treatment-naïve wet age-related macular degeneration (AMD).